Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q13191
UPID:
CBLB_HUMAN
Alternative names:
Casitas B-lineage lymphoma proto-oncogene b; RING finger protein 56; RING-type E3 ubiquitin transferase CBL-B; SH3-binding protein CBL-B; Signal transduction protein CBL-B
Alternative UPACC:
Q13191; A8K9S7; B7WNM4; Q13192; Q13193; Q3LIC0; Q63Z43; Q8IVC5
Background:
E3 ubiquitin-protein ligase CBL-B, also known as Casitas B-lineage lymphoma proto-oncogene b, plays a pivotal role in cellular processes by transferring ubiquitin to substrates, promoting their degradation. It regulates critical signal transduction pathways in T-cells, B-cells, and potentially in EGFR signaling, highlighting its importance in immune response and cellular homeostasis.
Therapeutic significance:
Understanding the role of E3 ubiquitin-protein ligase CBL-B could open doors to potential therapeutic strategies. Its involvement in key immune pathways suggests that modulating its activity could offer new avenues for treating immune-related disorders.